Last updated: 8 January 2019 at 3:54am EST

Cindy Driscoll Net Worth



Cindy Driscoll biography

Cindy Driscoll serves as Vice President - Finance of the Company. She has served as the Company’s Vice President, Finance since June 2017. Prior to joining the Company, Ms. Driscoll worked at Tokai Pharmaceuticals, Inc. (“Tokai”), from June 2011 to June 2017, most recently as the vice president of finance from September 2014 to June 2017, where she oversaw all finance and administrative operations for the publicly-traded company, including supporting its 2014 initial public offering. Ms. Driscoll earned her undergraduate degree in economics from the State University of New York at Oswego and completed her Master of Business Administration at Suffolk University.



How old is Cindy Driscoll?

Cindy Driscoll is 55, she's been the Vice President - Finance of Magenta Therapeutics Inc since 2020. There are 7 older and 13 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.

What's Cindy Driscoll's mailing address?

Cindy's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.

Insiders trading at Magenta Therapeutics Inc

Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third..., and Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.



What does Magenta Therapeutics Inc do?

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.



What does Magenta Therapeutics Inc's logo look like?

Magenta Therapeutics Inc logo

Magenta Therapeutics Inc executives and stock owners

Magenta Therapeutics Inc executives and other stock owners filed with the SEC include: